The earnings call presented a positive outlook due to the significant progress in accelerating NEPHRO study enrollment, reducing cash operating expenses, and advancing regulatory interactions. However, challenges with supply chain issues and reliance on future financing were noted. Despite these challenges, the overall sentiment is positive due to the significant progress and strategic adjustments made.

Company Guidance -

Q3 2025

In the Talphera Second Quarter 2025 Financial Results Conference Call, the company provided significant updates on their NEPHRO clinical study, highlighting an acceleration in patient enrollment. The study size was reduced from 166 to 70 patients, facilitating faster enrollment, with nine patients enrolled over the last six weeks. Additionally, six new clinical sites are expected to start enrolling by the end of the third quarter. The company's cash operating expenses for the second quarter of 2025 were reported at $3.7 million, down from the previous year's $4.3 million. Talphera also reduced its 2025 cash operating expense guidance to $16-$17 million. The company had a cash balance of $6.8 million as of June 30, 2025, which, along with expected proceeds from milestone-driven financing tranches, is projected to support operations through study completion.

Acceleration of NEPHRO Study Enrollment

The NEPHRO study enrollment has more than doubled since May, with a strong acceleration in the enrollment rate over the last 6 weeks, primarily from new target profile sites. The number of enrolled patients increased significantly due to strategic changes, including reducing the study size and adjusting site profiles.

Reduction in Cash Operating Expenses

Talphera reduced its 2025 expected cash operating expense guidance to $16-17 million from the previous $17-19 million. The cash operating expenses for Q2 2025 were $3.7 million, a decrease from $4.3 million in Q2 2024, mainly due to reductions in personnel and administrative expenses.

Progress in Compassionate Use IDE

Talphera is advancing a compassionate use IDE for nafamostat with institutions interested in using it for patients not responding well to other anticoagulants. This indicates growing interest and potential market demand for nafamostat.

Breakthrough Designation from FDA

Nafamostat has a breakthrough designation from the FDA, which facilitates efficient access to the agency and quick review and response times, minimizing regulatory risks.

Talphera (TLPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TLPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.13 / -	-0.13	―	―	―
Aug 14, 2025	2025 (Q2)	-0.13 / -0.10	-0.15	33.33% (+0.05)	―
May 14, 2025	2025 (Q1)	- / -0.10	-0.16	37.50% (+0.06)	―
Mar 31, 2025	2024 (Q4)	-0.14 / -0.10	-0.16	37.50% (+0.06)	―
Nov 13, 2024	2024 (Q3)	-0.19 / -0.13	-0.08	-62.50% (-0.05)	―
Aug 14, 2024	2024 (Q2)	-0.21 / -0.15	-0.41	63.41% (+0.26)	―
May 14, 2024	2024 (Q1)	-0.25 / -0.16	-0.75	78.67% (+0.59)	―
Mar 06, 2024	2023 (Q4)	-0.20 / -0.25	-1	75.00% (+0.75)	―
Nov 08, 2023	2023 (Q3)	-0.28 / -0.08	-0.94	91.49% (+0.86)	―
Aug 10, 2023	2023 (Q2)	-0.53 / -0.41	9.6	-104.27% (-10.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TLPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.43	$0.42	-2.33%
May 14, 2025	$0.51	$0.49	-3.92%
Mar 31, 2025	$0.50	$0.53	+6.00%
Nov 13, 2024	$0.89	$0.66	-25.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Talphera (TLPH) report earnings?

Talphera (TLPH) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Talphera (TLPH) earnings time?

Talphera (TLPH) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TLPH EPS forecast?

TLPH EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing